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Abstract: Thrombotic thrombocytopenic purpura (TTP) is a multisystemic microvascular 
disorder that may be caused by an imbalance between unusually large von Willebrand factor 
multimers and the cleaving protease ADAMTS13. In acquired TTP, especially in secondary 
TTP with various underlying diseases, the diagnosis is difficult because there are many cases 
that do not exhibit severe deficiency of ADAMTS13 or raised levels of ADAMST13 inhibitors. 
It is well known that collagen disease, malignancy, and hematopoietic stem cell transplantation 
can be underlying conditions that induce TTP. However, TTP induced by acute pancreatitis, 
as experienced by our patient, has rarely been reported. Our patient completely recovered with 
treatments using steroids and plasma exchange (PE) only. In cases where patients develop 
acute pancreatitis with no apparent causes for hemolytic anemia and thrombocytopenia, the 
possibility of TTP should be considered. Treatments for TTP including PE should be evaluated 
as soon as a diagnosis is made.
Keywords: thrombotic thrombocytopenic purpura, ADAMTS13, acute pancreatitis, plasma 
exchange
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder.1,2 It is 
recognized that TTP may be induced by an imbalance between unusually large von 
Willebrand factor multimers (ULVWFM) and a disintegrin-like metalloprotease with 
thrombospondin type 1 motif 13 (ADAMTS13), which often leads to the formation 
of microthromboses.1–3 ADAMTS13 cleaves ULVWFM with platelet aggregation. 
Severe deficiency of ADAMTS13 activity or excessive ULVWFM can cause micro-
thrombosis and result in TTP.
Congenital TTP (Upshaw–Schulman syndrome) is characterized by the absence 
or severe deficiency of ADAMTS13 activity by mutations in the ADAMTS13 gene. 
Acquired idiopathic TTP without underlying diseases generally has severe deficiency of 
ADAMTS13 activity caused by anti-ADAMTS13 autoantibodies. However, acquired 
secondary TTP due to various underlying diseases often does not show a severe 
deficiency of ADAMTS13 activity or the presence of ADAMTS13 inhibitors. TTP 
without severe ADAMTS13 deficiency is described as thrombotic microangiopathy 
(TMA).3 It is well known that these secondary TTPs are associated with collagen 
disease, malignancy, and hematopoietic stem cell transplantation.1,3 Furthermore, on 
rare occasions, acute pancreatitis can also be a trigger for TTP.4,5
Since the discovery that plasma exchange (PE) is an effective treatment for TTP, the 
survival of patients with TTP has dramatically increased.6 However, in secondary TTP 
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with normal or moderately reduced ADAMTS13 activity and 
no evidence of ADAMTS13 inhibitor, PE is not effective in 
many cases.7 We report a case of secondary TTP induced by 
acute pancreatitis, in which PE was effective.
Case report
A woman in her forties with acute epigastric pain and 
vomiting had been admitted. Computed tomography scan 
had revealed an enlargement of the pancreas. Common bile 
duct stones were not detected. She had been diagnosed with 
acute pancreatitis caused by alcohol and had started having 
treatment for this condition. On day 1, amylase was high 
at 1614 U/L. The number of white blood cells was also 
high at 155 × 102/µL. Hemoglobin (Hb) was slightly low 
at 10.8 g/dL. Platelet counts were high at 45.7 × 104/µL 
(Table 1). Therefore, initially, clinical symptoms and 
laboratory data only showed signs of acute pancreatitis. 
Amylase was decreased on day 3 and the symptoms of 
pancreatitis were resolving. However, on day 4, she had 
an unexplained sharp fall in Hb and platelet counts, which 
were 4.2 g/dL and 2.7 × 104/µL, respectively. She was 
transfused with platelet cells (PC) 10 units (U) and red cell 
concentrate 6 U. Despite the transfusion, she showed no 
improvement. She was transferred to our hospital on day 5 
to investigate anemia.
Laboratory data on admission to our hospital (day 5) 
are shown in Table 2. They showed hemolytic anemia 
and thrombocytopenia; Hb and platelet counts were low 
at 7.4 g/dL and 2.4 × 104/µL, respectively. Lactate dehydro-
genase was high at 2121 U/L. Total bilirubin was also high 
at 3.0 mg/dL. Haptoglobin was extremely low at less than 
10 mg/dL. The results also showed renal failure; creatinine 
was 2.51 mg/dL and the estimated glomerular filtration rate 
Table 1 Laboratory data on pre-admission
Days from diagnosis day 1 day 2 day 3 day 4
WBC × 102/µL 155 NT 232 141
RBC × 104/µL 478 NT 360 203
Hb g/dL 10.8 NT 7.5 4.2
PLT × 104/µL 45.7 NT 10.2 2.7
AMY U/L 1614 NT 473.5 NT
T-Bil mg/dL 0.34 NT 2.88 NT
D-Bil mg/dL 0.1 1.1 NT NT
LDH U/L 317 2209 NT NT
CRTN mg/dL 0.37 NT 2.72 NT
CRP mg/dL 0.28 NT 14.98 NT
Abbreviation: ns: WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; 
PLT, platelets; AMY, amylase; T-Bil, total bilirubin; D-Bil, direct bilirubin; LDH, lactate 
dehydrogenase; CRTN, creatinine; CRP, C-reactive protein; NT, not tested.
Table 2 Laboratory data on admission (= day 5)
WBC 162 × 102/µL
RBC 309 × 104/µL
Hb 7.4 g/dL
Ht 22.4%
PLT 2.4/µL
schistocytes 3+ (.5%)
AMY 96 U/L
P-AMY 87 U/L
AST 77 U/L
ALT 27 U/L
T-Bil 3 mg/dL
D-Bil 0.8 mg/dL
LDH 2121 U/L
BUN 43 mg/dL
CRTN 2.51 mg/dL
eGFR 17 ml/min/1.73m2
CRP 14.5 mg/dL
SAA 690 µg/dL
Hp ,10 mg/dL
PT 119%
PT-INR 0.91
APTT 26.1 sec
FBG 316 mg/dL
AT III 76%
D-Ddimer 8.5 µg/dL
Direct Coombs (–)
Abbreviations: WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; 
PLT,  platelets;  AMY,  amylase;  T-Bil,  total  bilirubin;  D-Bil,  direct  bilirubin;  LDH, 
lactate dehydrogenase; CRTN, creatinine; CRP, C-reactive protein; BUN, blood 
urea  nitrogen;  AST,  aspartate  aminotransferase;  ALT,  alanine  aminotransferase; 
eGFR, epidermal growth factor receptor; SAA, serum amyloid; Hp, haptoglobin; 
PT, prothrombin time; PT-INR, prothrombin international normalized ratio; APTT, 
activated partial thromboplastin time; FBG, fibrinogen; AT III, antithrombin III.
was 17 mL/minute/1.73 m2. Although D-dimer was high at 
8.5 µg/dL, prothrombin time and activated partial thrombo-
plastin time and fibrinogen were normal. The results did not 
  suggest   disseminated intravascular coagulation. There were 
schistocytes in her peripheral blood smear (3+; .5%). Both 
direct and indirect Coombs tests were negative. The patient’s 
body temperature was 37.4°C. She had no neurological 
  abnormalities. With additional tests on day 6, ADAMTS13 
activity was 60% and ADAMTS13 inhibitor was not 
detected. These tests were determined by a chromogenic 
ADAMTS13-act-ELISA (ADAMTS13 ELISA Kit: Kainos 
Inc, Tokyo, Japan).8
The patient was initially treated with prednisolone 
(30 mg/day). She was transfused with red cell concentrate 
4 U on day 6. Her symptoms and progress after developing 
acute pancreatitis were relatively similar to those from some 
reports of TTP induced by acute pancreatitis. On day 7, she 
was diagnosed with acquired secondary TTP.
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The patient started treatment with PE, receiving a total of 
five treatments. She received PE for 4 consecutive days (from 
day 7 to day 10) and on day 13 (Figure 1). The dose of fresh 
frozen plasma (FFP) for PE was 3600 mL/day for the first 
4 days and 2700 mL/day for the last day. On day 7, Hb was 
8.8 g/dL and platelet counts were 0.8 × 104/µL before PE. On 
day 14, Hb and platelet counts were 7.7 g/dL and 46.4 × 104/µL, 
respectively. ADAMTS13 activity was 75% on day 17 and 
78% on day 31. The dose of   prednisolone was tapered. She did 
not require any additional treatments. She was discharged 
from our hospital on day 39. She has maintained remission 
for 1 year and has not suffered a relapse.
Discussion
TTP is clinically characterized by five typical symptoms: 
hemolytic anemia, thrombocytopenia, renal impairment, 
fever, and neurological disorders.1 However, none of these 
symptoms is a diagnostic characteristic for TTP. F  urthermore, 
it is rare to see all of them together before the disease signifi-
cantly develops. It is difficult to diagnose TTP from clinical 
features. In contrast, measurement of ADAMTS13 activity 
and its inhibitor are useful for the diagnosis of TTP. At the 
same time, in cases where ADAMTS13 activity is normal 
or moderately reduced with no presence of the inhibitor, we 
need to examine the patient history carefully.
Although there are some case reports of TTP associated 
with acute pancreatitis, this appears to be rare.3–5 Among 
919 patients who were registered as having TMA across 
Japan during the period 1998–2008, which comprised a 
TMA database of Nara Medical University reported by 
Fujimura et al, no cases of TMA associated with acute 
pancreatitis were recorded.3 In the clinical course of our 
patient, there were schistocytes in her peripheral blood 
smear and she did not have any effects from PC transfusion. 
Although we suspected that her symptoms were caused 
by TTP, it was not easy to make a definite diagnosis of 
TTP because this was occurring while acute pancreatitis 
was developing and ADAMTS13 activity deficiency was 
moderate without its inhibitor. McDonald et al described 
the following findings, which were based on seven cases 
of TTP induced by acute pancreatitis: the median time 
from presentation with pancreatitis to the development of 
laboratory or clinical features of TTP was 3 days; with the 
onset of TTP, all patients had a fall in Hb and platelets; 
and at the time of onset of TTP, the disease markers for 
pancreatitis were improving.4   Similar findings were also 
observed in our patient. In   addition, McDonald et al noted 
that ADAMTS13 activity was only moderately reduced with 
no presence of the inhibitor.4 Similar findings have been 
reported in other studies.5,9 We speculate that ADAMTS13 
activity was moderately reduced at the onset of TTP because 
it was slightly lower than that on day 31.
The relationship between acute pancreatitis and TTP is 
unclear. However, it is recognized that ADAMTS13 activity 
is reduced by acute inflammatory disease.10 I  nflammation 
with acute pancreatitis results in not only damage to the 
pancreas but it also impairs the microcirculation in multiple 
organs.11 An increase in inflammatory cytokines in the 
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Figure 1 Clincial course of the patient.
Abbreviations: Hb, hemoglobin; PSL, prednisolone; Plt, platelets; RCC, red cell concentrate; PC, platelet cells; FFP, fresh frozen plasma.
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peripheral blood of patients with acute pancreatitis is now 
considered as one of the causes of TTP.12 Morioka et al 
reported that concentrations of interleukin 6 (IL-6), IL-8 
and tumor necrosis factor-α were increased in patients with 
acute pancreatitis.11,13 These cytokines can be a prognostic 
factor with severe acute pancreatitis. In fact, it has been 
demonstrated in vitro that IL-6 interrupts or inhibits cleavage 
of ULVWF by ADAMTS13, and IL-8 and TNF-α precipi-
tate a release of ULVWF by activating endothelial cells.14 
This could lead to decreased ADAMTS13 activity due to 
IL-6 and increased ULVWF due to IL-8 and TNF-α, which 
suggests an association of microthrombosis with excessive 
platelet activation. It is believed that an imbalance between 
enzyme and substrate caused by inflammatory cytokines 
could trigger TTP.15,16
The guidelines of the British Committee for   Standards 
in Haematology recommend that PE is continued for 
a minimum of 2 days after the platelet counts return 
to   normal (.150,000/mm3) for TTP.17,18 In our case, after the 
patient was diagnosed with TTP, she began treatment with PE 
immediately. Her platelet counts recovered well after having 
four treatments with PE. This rapid recovery is the reason 
why we only gave one additional PE and the dose of FFP was 
decreased after her platelet counts returned within the nor-
mal range. Platelet counts showed an improvement between 
days 7 and 14 but Hb levels did not improve. However, Hb 
showed a slower response to PE than platelet counts.1 In fact, 
the patient’s Hb gradually recovered after recovering from 
thrombocytopenia (Figure 1). The effect of PE in TTP is well 
known. Inflammatory cytokines could be a factor in precipitat-
ing TTP as mentioned above. This suggests that PE also plays 
an important role in the removal of these cytokines in addition 
to supplementing ADAMTS13 and removing ULVWF. This 
could ensure that patients return to a normal balance between 
ADAMTS13 and ULVWF more effectively.
We can assume that our patient progressed well with 
appropriate treatments. She has not had any relapses. PE 
provided a clinical benefit for our patient who developed 
acquired secondary TTP induced by acute pancreatitis. 
The etiologies of TTP are diverse. The association between 
TTP and acute pancreatitis are still unknown and this has 
rarely been reported. However, it is becoming apparent that 
pancreatitis can trigger TTP by a pathogenic mechanism 
associated with inflammatory cytokines. In cases where a 
patient who is developing pancreatitis has a sharp fall in Hb or 
platelet counts, the possibility of TTP should be considered, 
especially with the finding of schistocytes in a blood smear. 
A prompt diagnosis of TTP is important to be able to begin 
immediate treatment.
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